Kaare Bjerregaard-Andersen, PhD, received a doctorate from Oslo University, where he worked to characterize membrane protein structure, specifically regions of intrinsic disorder within a regulatory region of a bicarbonate transporter protein. He also developed an enzymatic assay for a isatin, a product of amino acid metabolism, to facilitate its development as a biomarker. As a postdoctoral fellow at Oslo University (2014-2018), Dr. Bjerregaard-Anderson continued working on protein structures, with a focus on engineering an antibody that can recognize a tumor-associated surface sugar. At Lundbeck (Copenhagen, Denmark) since 2018, he is focused on alpha-synuclein structural biology and pathology, developing a seed amplification assay (SAA) for detecting aggregated alpha-synuclein as a biomarker, and he is a project leader on an early program to develop pathology-specific antibodies.